Horizon Therapeutics (HZNP) Tops Q1 EPS by 20c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Horizon Therapeutics (HZNP) PT Lowered to $162 at Goldman Sachs
May 4, 2022 3:50 PM EDTGoldman Sachs analyst Madhu Kumar lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $162.00 (from $169.00) while maintaining a Buy rating following earnings.
The analyst commented, "Recognizing near-term headwinds for Tepezza related to carryover from omicron delays from 1Q22 into 2Q22,... More
